Transcenta Holding Limited
創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

The board (the "**Board**") of directors (the "**Directors**") of Transcenta Holding Limited (the "**Company**" or "**Transcenta**", and together with its subsidiaries, the "**Group**") is pleased to announce the unaudited consolidated results of the Group for the six months ended June 30, 2026 (the "**Reporting Period**"), together with the comparative figures for the corresponding period in 2025. These results were based on the unaudited consolidated interim financial statements of the Group for the Reporting Period, which were prepared in accordance with IFRS Accounting Standards ("**IFRS**") and reviewed by the audit committee of the Company (the "**Audit Committee**").

In this announcement, "we", "us" and "our" refer to the Company and where the context otherwise requires, the Group. Certain amounts and percentage figures included in this announcement have been subject to rounding adjustments, or have been rounded to one or two decimal places. Any discrepancies in any table, chart or elsewhere between totals and sums of amounts listed therein are due to rounding.

FINANCIAL HIGHLIGHTS

IFRS Accounting Standards ("IFRS") Measures:

Revenue increased from RMB2.7 million for the six months ended June 30, 2025 to RMB23.6 million for the six months ended June 30, 2026, primarily attributable to the increase in out-licensing revenue and CDMO services.

Other income decreased by RMB9.2 million from RMB9.4 million for the six months ended June 30, 2025 to RMB0.2 million for the six months ended June 30, 2026, primarily due to the decrease in government subsidies recognized during the six months ended June 30, 2026.

Other gains and losses decreased by RMB1.2 million from a loss of RMB1.2 million for the six months ended June 30, 2025 to a loss of nil for the six months ended June 30, 2026, primarily attributable to exchange rate fluctuations.

Research and development ("**R&D**") expenses decreased by RMB25.2 million from RMB76.7 million for the six months ended June 30, 2025 to RMB51.5 million for the six months ended June 30, 2026, primarily attributable to our key pipeline advancement and resource reprioritization.

Administrative and selling expenses decreased by RMB0.2 million from RMB28.3 million for the six months ended June 30, 2025 to RMB28.1 million for the six months ended June 30, 2026, primarily attributable to cost control.

As a result of the above factors, loss and total comprehensive expenses for the period decreased by RMB41.5 million from RMB108.8 million for the six months ended June 30, 2025 to RMB67.3 million for the six months ended June 30, 2026, primarily attributable to the decrease in R&D investment related to our pipeline advancement.

Non-IFRS Accounting Standards ("Non-IFRS") Measures:

Revenue increased from RMB2.7 million for the six months ended June 30, 2025 to RMB23.6 million for the six months ended June 30, 2026, primarily attributable to the increase in out-licensing revenue and CDMO services.

Other income decreased by RMB9.2 million from RMB9.4 million for the six months ended June 30, 2025 to RMB0.2 million for the six months ended June 30, 2026, primarily attributable to the decrease in government subsidies recognized during the six months ended June 30, 2026.

Research and development expenses excluding the share-based payment expenses decreased by RMB20.3 million from RMB70.8 million for the six months ended June 30, 2025 to RMB50.5 million for the six months ended June 30, 2026, primarily attributable to the decrease in investment on our pipeline advancement and resource prioritization.

Administrative and selling expenses excluding the share-based payment expenses increased by RMB1.9 million from RMB24.9 million for the six months ended June 30, 2025 to RMB26.8 million for the six months ended June 30, 2026, primarily attributable to certain non-recurring expenses recognized during the Reporting Period.

Adjusted loss and total comprehensive expenses for the period excluding the effect of share-based payment expenses decreased by RMB34.4 million from RMB99.4 million for the six months ended June 30, 2025 to RMB65.0 million for the six months ended June 30, 2026, primarily due to the decrease of R&D investment related to our pipeline advancement.

BUSINESS HIGHLIGHTS

Summary

During the Reporting Period, the Company delivered solid execution across its oncology and non-oncology pipelines, with continued progress in clinical development and portfolio advancement.

In oncology, the Company's Claudin18.2-targeting antibody osemitamab (TST001) achieved significant late-stage progress in the treatment of patients with Claudin18.2-expressing locally advanced or metastatic gastric or gastroesophageal junction ("**G/GEJ**") cancer. Updated efficacy analyses from Cohort G of the Phase I/II TranStar102 study, presented at ASCO in June 2025 and ESMO Asia in December 2025, further demonstrated the robust clinical activity of osemitamab in combination with nivolumab and CAPOX as the first-line treatment of patients with G/GEJ cancer. Among the 26 patients with high/medium CLDN18.2 expression (≥40% ≥2+) and known PD-L1 CPS, the median progression-free survival reached 16.6 months, with an objective response rate of 68% and a median duration of response of 18.0 months, at a median follow-up of 25.8 months. Among the 10 patients with CLDN18.2 ≥40% ≥2+ and PD-L1 CPS≥1, the ORR was 80%, median DoR was 19.4 months and median PFS was 16.6 months. The Company also obtained regulatory clearances from the U.S. Food and Drug Administration (FDA), China Center for Drug Evaluation (CDE), and South Korea Ministry of Food and Drug Safety for the planned global Phase III trial (TranStar301). In addition, patents relating to osemitamab (TST001) were granted by the China National Intellectual Property Administration, the Federal Service for Intellectual Property of the Russian Federation, and the Intellectual Property Department of Hong Kong, further strengthening the intellectual property position of the program. Preclinical data for TST001 were presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026 and demonstrated potent anti-tumor activity in pancreatic cancer models.

The Company continued to advance discussions for the development and commercialization of osemitamab (TST001) with multiple global and regional pharmaceutical companies. Several parties are conducting due-diligence reviews and/or proceeding with term-sheet and contract level negotiations covering global and regional collaboration scopes. The Company has also garnered term sheet-level interest from global and regional investment institutions, with which the Company has been in active discussions to secure funding for the asset. Pending the successful completion of these partnerships or funding, the Company expects to initiate the TranStar301 Phase III trial.

Beyond osemitamab (TST001), the Company also made solid progress in advancing its early next-generation oncology pipeline, which includes Ozekibart, TST003, TST013, TST106, and TST198. Regarding ozekibart, for which the Company holds exclusive rights to develop and commercialize in Greater China, the Company's partner Inhibrx announced U.S. FDA acceptance of BLA for ozekibart in patients with conventional chondrosarcoma with a PDUFA goal date set for April 14, 2027. Given these positive developments, the Company is currently evaluating the most effective and efficient way to advance ozekibart in Greater China. Preclinical data for TST013, the humanized anti-LIV1 antibody-drug conjugate, were presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026 and demonstrated potent anti-tumor activity in PDX models of metastatic hormone positive and HER2 negative breast cancer and in castration resistant prostate cancer models, supporting the continued development of the program. Preclinical data of TST198, an engineered and site specific conjugated anti-Claudin18.2 antibody-based radiopharmaceutical developed using Transcenta's SEAR RDC platform, was presented at the XDC Congress in March 2026 and demonstrated significantly improved reduction in liver/spleen uptake and enhanced specific retention in tumor, resulting in long-lasting anti-tumor activity in multiple Claudin 18.2 positive tumor models.

In the non-oncology area, the Company is a leading player in the field of osteoporosis and is investing in developing multiple innovative best-in-class and first-in-class agents for the treatment of bone disorders. In particular, the Company is in the process of initiating the phase IIb trial of blosozumab, a potential best-in-class anti-sclerostin antibody with unique binding epitope and potential safety profile advantage, in post-menopausal women with osteoporosis in China. Recent regulatory guidance issued in December 2025 by FDA allowed the use of total hip Bone Mineral Density (BMD) as a validated surrogate endpoint to support registration enabling trials of investigational therapies for post-menopausal women with osteoporosis at risk for fracture. This allows for more efficient clinical trials, potentially enabling faster approval of new osteoporosis treatments and improving patient access at significantly lower development cost. In addition, TST002's low-frequency dosing regimen could offer significant clinical and commercial advantage over existing anti-sclerostin therapy.

The Company also continued to expand and diversify its non-oncology pipeline and is actively advancing next-generation anti-osteoporosis agents such as TST973 and TST901 as well as agents for the treatment of autoimmune disease such as TST801, a bifunctional antibody targeting BAFF and APRIL, and TST808, a second generation long-acting anti-APRIL antibody.

In parallel, the Company made solid and encouraging progress in partnership discussions relating to certain proprietary bioprocessing technologies and intellectual property. The Company successfully entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. ("**EirGenix**") (TWSE: 6589) to advance integrated continuous biomanufacturing and expand global access to affordable biologics. During the Reporting Period the Company has received both upfront and first milestone payments and is eligible to receive additional milestone payment as well as future royalty payments associated with the commercial use of the licensed technologies. This partnership validates the value of this technology platform. This collaboration further strengthens the Company's technology platform, validates its differentiated capabilities, and enhances its long-term growth and value creation potential. The Company continues to pursue additional technology out-licensing and collaborations as a means for additive value creation.

Clinical Programs Achievements

Osemitamab (TST001, A Humanized ADCC Enhanced Claudin18.2 mAb for Solid Tumors)

- In March 2025, the Hong Kong patent for TST001 was granted to the Company by the Intellectual Property Department of Hong Kong.

- In June 2025, the Company presented encouraging updated results from the Cohort-G of an ongoing Phase II trial of osemitamab (TST001) plus nivolumab and CAPOX as the first-line treatment for patients with advanced G/GEJ cancer (TranStar102). The findings were showcased in a poster presentation (Abstract #4032) at the 2025 ASCO Annual Meeting in Chicago, IL, U.S. In the 26 patients who have CLDN18.2 expression on at least 40% of the tumor cells with 2+ or 3+ intensity per 14G11 IHC LDT assay and known PD-L1 status, the mOS reached 21.7 months and the median progression-free survival (mPFS) was 16.6 months. The confirmed objective response rate (cORR) was 68% with a median duration of response (mDoR) of 16.5 months in this population.

- In December 2025, the Company presented an updated efficacy analysis of Cohort G by CLDN18.2 and PD-L1 expression from the Phase I/II TranStar102 trial of osemitamab (TST001) plus nivolumab and CAPOX in first-line Gastric/Gastroesophageal Junction (G/GEJ) cancer at ESMO Asia. The exploratory efficacy analysis indicates that better progression-free survival outcomes in patients with higher CLDN18.2 expression (≥40% ≥2+) compared to lower CLDN18.2 expressors (<40%, ≥2+) in both PD-L1 CPS<1 and ≥ 1 subgroups, which indicated the potential treatment benefit of osemitamab is consistent regardless of PD-L1 expression. In particular, in the subgroup patients with CLDN18.2 ≥40% ≥2+ and PD-L1 CPS≥1, the ORR was 80%, median DoR was 19.4 months and median PFS was 16.6 months. This new analysis reinforces the encouraging clinical benefit of the osemitamab triple combination regimen in the ongoing study.

- In April 2026, preclinical data for TST001 were presented at the American Association for Cancer Research (AACR) Annual Meeting and demonstrated potent anti-tumor activity in pancreatic cancer models.

- The Company continued the collaboration with Agilent, a world leader in CDx development. The development of Claudin18.2 companion diagnostics (CDx) has advanced as planned to support the TranStar301 global Phase III pivotal trial of osemitamab (TST001) in combination with checkpoint inhibitor and chemotherapy as the first-line treatment in patients with Claudin18.2 expressing locally advanced or metastatic G/GEJ adenocarcinoma.

Blosozumab (TST002) (A Humanized Sclerostin mAb for Osteoporosis)

The Company is in the process of initiating the phase IIb trial of blosozumab, a potential best-in-class anti-sclerostin antibody with unique binding epitope and potential safety profile advantage, in post-menopausal women with osteoporosis in China. Recent regulatory guidance issued in December 2025 by FDA allowed the use of total hip Bone Mineral Density (BMD) as a validated surrogate endpoint to support clinical trials of investigational therapies for post-menopausal women with osteoporosis at risk for fracture. This allows for more efficient clinical trials, potentially enabling faster approval of new osteoporosis treatments and improving patient access at significantly lower development cost. In addition, TST002's low frequent dosing regimen could offer significant clinical and commercial advantage over existing anti-sclerostin therapy.

Research/Early Development Update

TST106 (Bispecific ADC Candidate targeting CLDN18.2 positive solid tumors)

- TST106 is a humanized bispecific antibody-based drug conjugate (ADC) targeting CLDN18.2 and an undisclosed tumor antigen expressed in multiple tumor types. CLDN18.2 is a clinically validated tumor antigen in gastric and pancreatic cancer, it is also overexpressed in lung cancer and other solid tumors. TST106 displayed excellent profile of selective killing of dual expressing cells of expressing both Claudin 18.2 and the other tumor associated antigen in vitro. In vivo it also displayed potent anti-tumor activity in models of Claudin 18.2 expressing tumors. The Company has since initiated the IND-enabling studies to further advance this program. This bispecific program provides a potential safer and more efficacious agent for Claudin 18.2 positive tumors.

TST198 (A First-in-class Claudin18.2 Targeting RDC)

- TST198 is a first-in-class Claudin 18.2 targeting RDC optimized with specific tumor targeting to address unmet needs in solid tumors. RDC offers a potential differentiated approach to address payload resistance in patients pre-exposed to antibody drug conjugates. Leveraging its proprietary SEAR RDC platform, the Company has obtained desired drug targeting and promising anti-tumor activity data for the lead RDC in both in vitro and in vivo studies. Further preclinical testing is on-going.

- In March 2026, preclinical data of TST198 was presented at the 2026 XDC Congress and demonstrated significantly improved reduction in liver/spleen uptake and enhanced specific retention in tumor, resulting in long-lasting anti-tumor activity in multiple Claudin 18.2 positive tumor models.

TST786 (A First-in-Class Next Generation Trispecific Antibody Candidate Targeting PD1-VEGF and GREMLIN-1)

- TST786 is a next generation trispecific antibody candidate targeting PD1, VEGF and GREMLIN-1. GREMLIN-1 is a stromal fibroblast derived regulatory protein and contributes to tumor metastasis and has been negatively associated with overall survival. Currently PD1-VEGF bispecifics have shown promising PFS benefits but OS benefit is to be confirmed. The Company's trispecific antibody not only has the potential to improve PFS benefits but also has a high probability of improving OS benefits by blocking tumor metastasis. The program is at preclinical stage.

TST013 (An ADC Candidate Targeting LIV-1, A Tumor Antigen Overexpressed in Multiple Solid Tumors)

- TST013 is a next generation ADC targeting LIV-1, a clinically validated tumor antigen for breast cancer. LIV-1 is also highly expressed in other solid tumors, including lung cancer, prostate cancer, etc. The ADC molecule combines the site-specific conjugation of TOPO-I inhibitor with an in-house humanized antibody that targets distinct epitope and has a prolonged PK profile. The Company has obtained exciting anti-tumor activity data in in vivo pharmacology studies for the ADC lead molecules and initiated the IND-enabling studies. Compared with the benchmark ADC, TST013 displayed significantly improved anti-tumor activity with a good tolerability profile at clinically relevant doses in animal models.

- The Company has completed further in vivo testing of the lead ADC in PDX mouse models for breast cancer, lung cancer and prostate cancer, and initiated the cell line and process development to support IND filing. The encourage data were presented at 2026 AACR annual meeting as the poster titled "Preclinical characterization of novel LIV1 antibody drug conjugates".

TST105 (A Bispecific ADC Candidate Targeting Biomarker Expressing Gastric Cancer and Other Solid Tumors)

- TST105 is a humanized bispecific antibody-based drug conjugate (ADC) targeting FGFR2b and an undisclosed tumor antigen. FGFR2b is a clinically validated tumor antigen in gastric cancer, and it is also overexpressed in lung cancer and other solid tumors. The Company has obtained promising anti-tumor activity data for the lead ADC in in vivo studies. In April 2025, the Company presented the preclinical study results at the AACR Annual Meeting. TST105, with a novel topoisomerase I inhibitor payload utilizing glycosyltransferase mediated site-specific conjugation, demonstrated significantly enhanced anti-tumor activity compared to MMAE-based ADCs in preclinical gastric and colorectal tumor models. The encouraging data presented at AACR underscores the transformative potential of TST105 in treating cancers with FGFR2b overexpression. The Company is committed to developing this promising candidate into a transformative therapy for patients globally.

TST801 (A Bifunctional Antibody Fusion Protein for Autoimmune Diseases)

- TST801 is a first-in-class bifunctional antibody fusion protein of an anti-BAFF antibody and a TACI receptor. BAFF and APRIL, two ligands for TACI receptor, are involved in regulating B cell activation and differentiation. Dual targeting of BAFF and APRIL is a validated approach for the treatment of several autoimmune diseases, including Systemic Lupus Erythematosus (SLE), Lupus nephritis (LN), IgA nephropathy (IgAN), Generalized myasthenia gravis (gMG), etc. TST801 has the potential of delivering improved efficacy in these diseases as well as other B-cell related autoimmune diseases. We have selected the lead molecule and initiated IND-enabling studies. The Company has completed the evaluation of TST801 versus other competing molecules in a mouse model of human Lupus nephritis (human BAFF overexpressing transgenic mice). TST801 demonstrated best-in-class profile in reducing memory B cells, double stranded DNA (dsDNA), Immunoglobulin A (IgA), Immunoglobulin M (IgM) and Immunoglobulin G (IgG), as well as reducing proteinuria and the kidney damage scores.

- The Company has completed the PK/PD study in non-human primates, and the data supports a less frequent dosing regimen compared with the benchmark molecules, and the final lead molecule was selected for the process development and IND-enabling studies.

TST808 (A Humanized Antibody Neutralizing APRIL, A Validated Key Target Regulating B/Plasma Cell Proliferation and Survival)

- TST808 is a humanized antibody neutralizing APRIL, a validated key target regulating B/plasma cell proliferation and survival. TST808 has improved properties in blocking B cell proliferation and signaling. It was engineered to achieve a longer half-life. TST808 has the potential of treating multiple autoimmune renal disorders including IgAN. The Company has obtained lead molecules and initiated IND-enabling studies. The Company has engineered a second generation biparatopic antibody and is under preclinical evaluation.

- The Company has completed the PK/PD study in non-human primates, and the data supports a less frequent dosing regimen compared with the benchmark molecules, and the final lead molecule was selected for the cell line development.

TST008 (A Bi-specific Antibody for MASP-2 and BAFF for Autoimmune Diseases)

- TST008 is a first-in-class bispecific antibody dual targeting MASP-2 and BAFF. TST008 has both effects on B cell and lectin complement pathway, which provides the potential of delivering better efficacy to diseases affected by both pathways, e.g. IgAN, SLE, LN, etc. As at the date of this announcement, it is at preclinical stage.

TST973 (A Long Acting Anti-Sclerostin Antibody for the Treatment of Osteoporosis)

- TST973 is a best-in-class antibody with prolonged half-life. TST973 is designed for the treatment of patients with severe osteoporosis at risk of fracture with less frequent dosing. As at the date of this announcement, it is at preclinical stage.

TST901 (A Long Acting Anti-Sclerostin based Bispecific Antibody for the Treatment of Osteoporosis)

- TST901 is a first-in-class bispecific antibody targeting both sclerostin and another undisclosed target and with prolonged half-life. TST901 is designed for the treatment of patients with severe osteoporosis at risk of fracture with less frequent dosing and multiple mechanism of actions. As at the date of this announcement, it is at preclinical stage.

Business Development Achievements

- The Company has continued the clinical trial collaboration with BMS for the osemitamab (TST001), checkpoint inhibitor and chemotherapy combination in the TranStar102 trial in China and in the TranStar101 trial in the U.S.

- The Company has advanced the collaboration with Agilent for our Claudin18.2 specific IHC CDx Assay to support the TranStar301 global Phase III pivotal trial of osemitamab (TST001) in combination with checkpoint inhibitor and chemotherapy.

- For osemitamab (TST001), the Company is engaged in active discussions with potential partners to support global and regional development and commercialization and has received multiple term sheets and contract level proposals, with negotiations ongoing.

- The Company is currently in active discussions on partnerships and collaborative opportunities for the Company's pipeline assets to leverage global expertise and resources of potential partners for development and commercialization. The Company is also evaluating strategic deal structures, including the formation of companies ("**NewCo**") to advance preclinical and clinical-stage assets with external funding, reducing risk for the parent company while enabling focused and efficient asset development, to accelerate time to market and maximize asset value.

- On December 29, 2025, the Company together with its wholly-owned subsidiary, HJB (Hangzhou) Co., Ltd* (杭州奕安濟世生物藥業有限公司) ("**HJB Hangzhou**") (collectively, the "**Licensor**"), entered into strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (TWSE: 6589), a global biopharmaceutical development and manufacturing company. During the Reporting Period, Transcenta has received substantial upfront and milestone payments, and is eligible to receive for future royalty payments associated with the commercial use of Transcenta's Highly Intensified Continuous Bioprocessing (HiCB) platform.

- The Company's in-house cell culture media ExcelPro CHO are being evaluated for performance against market standards for fedbatch and perfusion processes by multiple external partners, including several global leading companies of CHO cell culture media business. This provides opportunities for potential collaboration of global commercialization of ExcelPro CHO media.

CMC & CDMO Updates

Platform and technology development

- The Company continued to improve the in-house cell line expression system and is on track to make it available for the development of the internal programs as well as licensing to industry partners.

- The Company established perfusion media for perfusion process. The Company also established basal and feed media for fed-batch process. Those media are ready for commercialization.

- The Company established ADC and RDC cold conjugation development services. The Company's conjugation process and quality analysis platform empowering development of innovative XDC drugs.

CDMO business

- The Company has expanded its services in siRNA drug product development and increased its exposure to international markets.

- The Company has signed an integrated IND-enabling CMC service contract with a US biotech client for a bispecific antibody program.

- The Company has also signed a contract to provide resupply for GMP production of clinical trial material with an existing client.

- The Company has signed a new contract to support high concentration antibody formulation development.

- The Company has extended its services to clients in need of drug products in lyophilization dosage form.

- The Company has continued its efforts in engaging new customers for such services.

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

Transcenta is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and process development, uniquely positioned to advance high-impact biologic innovations with global commercial potential. Supported by a seasoned and international executive leadership team, with particular expertise research and clinical development, the Company is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders.

The Company has established a multi-region development strategy designed to enable efficient global registration and commercialization. The Company's lead asset, osemitamab (TST001), is a best-in-class anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. Osemitamab (TST001) has received regulatory clearances from the U.S. FDA, China CDE, and South Korea MFDS to initiate a global Phase III trial evaluating osemitamab (TST001) in combination with a checkpoint inhibitor and chemotherapy as the first-line treatment for Claudin18.2-expressing locally advanced or metastatic gastric and gastroesophageal junction (G/GEJ) adenocarcinomas. To support this pivotal study, the Company has developed a proprietary Claudin18.2 antibody for companion diagnostic assay development, strengthening its precision medicine approach and commercial readiness.

As a leading player for developing innovative anti-osteoporosis drugs, the Company is poised to capture the substantial market opportunity shaped by the FDA's recent regulatory guidance on the qualification of total hip BMD as a validated surrogate efficacy endpoint for Phase 3 clinical studies of osteoporosis. This greatly relieves the long-standing major challenge in the development of innovative anti-osteoporosis drugs when fracture prevention was required as the primary efficacy endpoint for Phase 3 clinical studies of anti-osteoporosis drugs, often requiring enrollment of thousands of patients, several years of study duration, and enormous investment. Blosozumab, as a potential best-in-class therapy, has reported outstanding BMD increasing efficacy and favorable safety profile in the early phase clinical trials. With its less-frequent dosing regimen and favorable safety/efficacy profile, blosozumab has the opportunity to be an important therapeutic agent for the treatment of patients with severe osteoporosis and could enable significant return on investment due to an aging population and substantial market opportunity in China.

Beyond osemitamab (TST001) and blosozumab (TST002), the Company's proprietary antibody discovery platform also enables the rapid generation of first-in-class and best-in-class therapeutic candidates, while its comprehensive CMC infrastructure supports seamless advancement from discovery through late-stage clinical development and commercialization. In addition, the Company's advanced translational science platform drives biomarker discovery to support precision medicine development, significantly improving clinical success probabilities and accelerating value realization.

The Company's HiCB™ bioprocessing platform delivers high-quality biologics at meaningfully lower production costs, providing a strong competitive advantage in scalability and margins. Leveraging its end-to-end CMC capabilities, the Company also offers this innovative bioprocessing technology and matching CHO cell culture media ExcelPro to external partners via non-exclusive licensing, which could generate recurring revenue that enhances operational sustainability.

The Company continues to execute its global growth strategy through strategic collaborations with leading international and domestic biopharmaceutical companies and academic institutions, spanning R&D, manufacturing, and commercialization. In parallel, the Company actively explores innovative transaction structures, including NewCo and asset-level partnerships, to accelerate market entry, optimize capital efficiency, and maximize asset value. Together, these initiatives strengthen global rights management, enhance financial resilience, and expand long-term commercial opportunities across its pipeline.

Our Product Pipeline

The Company has established a diversified and differentiated pipeline of more than one dozen molecules in oncology, bone disorders, autoimmune diseases, nephrology, and other disorders. All but two of its antibody candidates were generated in-house by its antibody discovery platform covering validated, partially validated, and novel biological pathways; two pipeline candidates, blosozumab (TST002) and ozekibart, were acquired through in-licensing. The following chart summarizes the drug candidates that are currently under development globally across various therapeutic areas as of the date of this announcement:



Source: Company

Abbreviations: PD-L1=Programmed death-ligand 1; TGFβ=Transforming growth factor beta; MASP-2=Mannan-binding lectin serine protease 2; IND=Investigational new drug; FIC=First-in-class; HPV=Human Papillomavirus; NSCLC=Non-small cell lung cancer; SLE=Systemic lupus erythematosus; LN=Lupus nephritis; TMA=Thrombotic microangiopathy; IgA nephropathy=Immunoglobulin A nephropathy; Mono=Monotherapy; Combo=Combination; Chemo=Chemotherapy; DR5=Death Receptor 5.

(1) Solid tumors in the "Indications" column include all tumor types other than hematologic malignancies. The particular tumor types as indications for each product depends on the mechanism of action of the corresponding drug candidate and emerging or established preclinical/clinical evidence. See the subsections headed "Clinical Development Plan" for each of our drug candidates in "Business" section of the Prospectus for the specific tumor types targeted for clinical development.

(2) Global in the "Clinical trial region" column represents Asia (including China), North America, South America, Europe and Oceania.

BUSINESS REVIEW

The Company has established a diversified and differentiated pipeline of more than one dozen molecules in oncology, bone disorders, nephrology and other disorders. In particular, the Company is proud to have developed its four best-in-class molecules, TST001, TST002, TST004, and TST808, and its six first-in-class molecules, TST106, TST198, TST003, TST786, TST801, and TST008. During 2025, the Company made significant progress with its pipeline assets in both oncology and non-oncology therapeutic areas and achieved multiple clinical and preclinical milestones that are listed as follows:

I. Oncology Program

The Company's oncology pipeline includes multiple innovative and differentiated biologic molecules targeting major cancer types. Several drug candidates, including osemitamab (TST001), TST003, and TST013, are designed to achieve anti-tumor activities with different mechanisms that are potentially synergistic with each other for indications with high unmet medical needs. The Company's key oncology candidates include:

1. Osemitamab (TST001), the Company's lead asset, is a potential best-in-class and differentiated antibody targeting Claudin18.2, a validated tumor associated antigen in several solid tumors, including but not limited to gastric and gastroesophageal cancer, pancreatic cancer and lung cancer. Approvals to launch a global Phase III registration trial (TranStar301) to develop osemitamab (TST001) in combination with checkpoint inhibitor and chemotherapy as the first-line treatment for Claudin18.2 expressing G/GEJ adenocarcinomas have been received from the U.S. FDA, China CDE and South Korea MFDS. Further explorations include other Claudin18.2 expressing tumors in addition to G/GEJ cancer.

2. Ozekibart is a fully human DR5 agonist, for which the Company holds exclusive rights to develop and commercialize in Greater China, the Company's partner Inhibrx announced U.S. FDA acceptance of BLA for ozekibart in patients with conventional chondrosarcoma with PDUFA goal date set for April 14, 2027. Given these positive developments, the Company is currently evaluating the most effective and efficient way to advance ozekibart in Greater China.

3. TST106 is a humanized bispecific antibody-based drug conjugate (ADC) targeting CLDN18.2 and an undisclosed tumor antigen expressed in multiple tumor types. The bispecific antibody is designed to force the antibody to only bind to tumor cells expressing dual antigens but not to CLDN18.2 expressing only normal gastric epithelial cells and thus improve safety and efficacy in the target population.

4. TST198 is a first-in-class Claudin18.2 targeting RDC optimized with specific tumor targeting to address unmet needs in solid tumors that have failed prior Claudin18.2 directed therapies including ADCs.

5. TST003 is a first-in-class humanized monoclonal antibody targeting GREMLIN-1, which blocks GREM1 signaling in the tumor microenvironment resulting in inhibition of tumor cell differentiation and growth and is currently being explored in solid tumors including CRC, CRPC etc.

6. TST786 is a first-in-class next generation trispecific antibody candidate targeting PD1-VEGF and GREMLIN-1.

7. TST013 is a next generation ADC targeting LIV-1, a clinically validated target, a candidate at preclinical stage with potential to target breast cancer and other tumor types.

8. TST105 is a bispecific ADC candidate targeting FGFR2b and an undisclosed tumor antigen at preclinical stage for biomarker expressing gastric cancer, lung cancer and other solid tumors.

The Company's portfolio regarding the aforementioned program also offers opportunities to cover additional unmet medical needs through combinations: for example, TST003 is highly synergistic with osemitamab (TST001) potentially enhancing the Claudin18.2 franchise through proprietary combinations.

Provided below is additional information regarding the oncology program.

1. Osemitamab (TST001) (A Humanized ADCC-enhanced anti-Claudin 18.2 mAb for Solid Tumors)

Osemitamab (TST001), the Company's lead asset, is a potential best-in-class and ADCC enhanced humanized antibody specifically targeting Claudin18.2 with high-affinity. Claudin18.2 is overexpressed in multiple tumor types, including G/GEJ cancer, pancreatic ductal adenocarcinoma (PDAC) and lung cancer. The Company's strategy is to lead the next wave of innovation by developing osemitamab (TST001) combination with the latest standard of care (i.e., chemotherapy + checkpoint inhibitor), delivering more effective treatment to patients with Claudin18.2 expressing solid tumors including G/GEJ cancer, PDAC and lung cancer.

In the first-line Claudin18.2 positive G/GEJ cancer, the combination of Claudin18.2 targeting antibody with chemotherapy has been validated by a competing molecule as an effective treatment option in two global Phase III trials. The competing molecule benefits around 38% of G/GEJ cancer patients, based on the data in its clinical trials. Osemitamab (TST001) is a second generation Claudin18.2 targeting antibody designed to have more potent anti-tumor activities than the competing molecule. It has higher binding affinity and more potent ADCC (antibody-dependent cellular cytotoxicity) than the competing molecule. ADCC accounts for the direct killing of cancer cells by the anti-Claudin18.2 antibody. Transcenta's preliminary clinical data indicates that osemitamab (TST001) has the potential to benefit a broader patient population (~55% of G/GEJ cancer patients). The Company's strategy in the first-line advanced or metastatic G/GEJ cancer is to offer patients the best-in-class next wave innovation with osemitamab (TST001) in combination with checkpoint inhibitor and chemotherapy for patients with Claudin18.2 expressing G/GEJ cancer.

The Company has made significant progress in 2025 in advancing the clinical development for osemitamab (TST001), which includes:

Recent Product Developments and Milestones

- In March 2025, the Hong Kong patent for Claudin18.2 was granted to the Company by the Intellectual Property Department of Hong Kong.

- In June 2025, the Company presented encouraging updated results from the Cohort-G of an ongoing Phase II trial of osemitamab (TST001) plus nivolumab and CAPOX as the first-line treatment for patients with advanced G/GEJ cancer (TranStar102). The findings were showcased in a poster presentation (Abstract #4032) at the 2025 ASCO Annual Meeting in Chicago, IL, U.S. In the 26 patients who have CLDN18.2 expression on at least 40% of the tumor cells with 2+ or 3+ intensity per 14G11 IHC LDT assay and PD-L1 known, the mOS was 21.7 months and the median progression-free survival (mPFS) was 16.6 months. The confirmed objective response rate (cORR) was 68% with a median duration of response (mDoR) of 16.5 months in this population.

- In December 2025, the Company presented updated efficacy analysis of Cohort G by CLDN18.2 and PD-L1 expression from the Phase I/II TranStar102 trial of osemitamab (TST001) plus nivolumab and CAPOX in first-line treatment for Gastric/Gastroesophageal Junction (G/GEJ) cancer at ESMO Asia. The exploratory efficacy analysis indicates better progression-free survival outcomes in patients with higher CLDN18.2 expression compared to lower CLDN18.2 expressors in both PD-L1 CPS<1 and ≥ 1 subgroups, which indicates the potential treatment benefit of osemitamab (TST001) is consistent regardless of PD-L1 expression. Among the 10 patients with CLDN18.2 ≥40% ≥2+ and PD-L1 CPS≥1, the ORR was 80%, median DoR was 19.4 months and median PFS was 16.6 months. This new analysis reinforces the encouraging clinical benefit of the osemitamab (TST001) triple combination regimen in the ongoing study.

- In April 2026, Preclinical data for TST001 were presented at the American Association for Cancer Research (AACR) Annual Meeting and demonstrated potent anti-tumor activity in pancreatic cancer models.

- The Company continued the collaboration with Agilent, a world leader in CDx development. The development of Claudin18.2 companion diagnostics (CDx) has advanced as planned to support the TranStar301 global Phase III pivotal trial of osemitamab (TST001) in combination with checkpoint inhibitor and chemotherapy as the first-line treatment in patients with Claudin18.2 expressing locally advanced or metastatic G/GEJ adenocarcinoma.

3. TST106 (Bispecific ADC Candidate targeting CLDN18.2 positive solid tumors)

TST106 is a humanized bispecific antibody-based drug conjugate (ADC) targeting CLDN18.2 and an undisclosed tumor antigen expressed in multiple tumor types. CLDN18.2 is a clinically validated tumor antigen in gastric and pancreatic cancers, it is also overexpressed in lung cancer and other solid tumors. Further development towards IND filing is ongoing.

4. TST198 (A First-in-class Claudin18.2 Targeting RDC)

TST198 is a first-in-class Claudin18.2 targeting RDC optimized with specific tumor targeting to address unmet needs in solid tumors. RDC offers a potential differentiated approach to address payload resistance in patients pre-exposed to antibody drug conjugates. The Company has obtained desired drug targeting and promising anti-tumor activity data for the lead RDC in both in vitro and in vivo studies. Further preclinical testing is on-going.

5. TST003 (A First-in-Class Humanized Anti-GREMLIN-1 Antibody)

TST003 is a first-in-class and high affinity humanized monoclonal antibody targeting GREMLIN-1, a regulatory protein that is highly expressed by stromal cells and tumor cells in diverse human carcinomas, especially in colon cancer, prostate cancer, gastric cancer, lung cancer, esophageal cancer, pancreatic ductal adenocarcinoma and breast cancer. It is currently tested in a global FIH trial at multiple clinical centers in the U.S. and China. Dose escalation as monotherapy has been completed. TST003 has demonstrated good safety and tolerability, and dose proportional PK profiles were observed.

6. TST786 (A First-in-Class Next Generation Trispecific Antibody Candidate Targeting PD1-VEGF and GREMLIN-1)

TST786 is a next generation trispecific antibody candidate targeting PD1-VEGF and GREMLIN-1. GREMLIN-1 is a stromal fibroblast regulatory protein and contributes to metastasis and has been negatively associated with overall survival. Currently PD1-VEGF bispecifics have shown promising PFS benefits but OS benefit is to be confirmed. The Company's trispecific antibody not only has the potential to improve PFS benefits but also has a high probability to improve OS benefits by blocking tumor metastasis. It is at preclinical stage.

Recent Product Developments and Milestones

- In 2025, the lead molecule has been obtained and preclinical testing is ongoing.

7. TST013 (An ADC Candidate Targeting LIV-1, A Tumor Antigen Overexpressed in Multiple Solid Tumors)

TST013 is a next generation ADC targeting LIV-1, a clinically validated tumor antigen for breast cancer. LIV-1 is also highly expressed in other solid tumors including lung cancer, prostate cancer, etc. The ADC molecule combines the site-specific conjugation of TOPO-I inhibitor, with an in-house humanized antibody that targets distinct epitope and has a prolonged PK profile. The Company has obtained exciting anti-tumor activity data in in vivo pharmacology study for the ADC lead molecules. Compared with the benchmark ADC, TST013 displayed significantly improved anti-tumor activity with a good tolerability profile at clinically relevant doses in animal models. The Company has also observed significant preclinical activities in lung cancer. As at the date of this announcement, it is at preclinical stage.

Recent Product Developments and Milestones

- The Company has completed further in vivo testing of the lead ADC in PDX mouse models for breast cancer, lung cancer and prostate cancer, and initiated the cell line and process development.

- The encouraging preclinical data were presented at 2026 AACR annual meeting as the poster titled "Preclinical characterization of novel LIV1 antibody drug conjugates".

8. TST105 (A Bispecific ADC Candidate Targeting Biomarker Expressing Gastric Cancer and Other Solid Tumors)

TST105 is a humanized bispecific antibody-based drug conjugate (ADC) targeting FGFR2b and an undisclosed tumor antigen. FGFR2b is a validated tumor antigen in gastric cancer, it is also overexpressed in lung cancer and other solid tumors. The Company is currently developing the bispecific ADC to improve therapeutic window. As at the date of this announcement, it is at preclinical stage.

Recent Product Developments and Milestones

- In April 2025, the Company presented the preclinical study results of TST105 at the AACR Annual Meeting. TST105, with a novel topoisomerase I inhibitor payload utilizing glycosyltransferase mediated site-specific conjugation, demonstrated significantly enhanced anti-tumor activity compared to MMAE-based ADCs in preclinical gastric and colorectal tumor models. The encouraging data presented at AACR underscore the transformative potential of TST105 in treating cancers with FGFR2b overexpression. The Company is committed to translating this promising candidate into a transformative therapy for patients globally.

II. Non-oncology Program

The Company's highly differentiated non-oncology pipelines target bone and autoimmune diseases (blosozumab (TST002), TST004, TST008, TST801, and TST808) that have large patient population and high unmet medical needs. The Company has focused on indications with huge market potential and aimed to form partnerships to accelerate product development.

The Company has been developing blosozumab (TST002), a Phase II stage agent targeting bone disorders as a lead asset. To further expand its current pipeline in autoimmune diseases, the Company is developing TST801, a first-in-class bi-functional antibody. This molecule also has the potential for the treatment of IgA nephropathy and other autoimmune diseases, such as SLE, a progressive disease affecting over three million people worldwide with early onset (age 18-44) and limited treatment options to slow down or stop the organ damages caused by the disease.

Provided below is additional information regarding the non-oncology program.

1. Blosozumab (TST002) (A Humanized Sclerostin mAb for Osteoporosis)

Blosozumab (TST002) is a humanized monoclonal antibody with neutralizing activity against sclerostin for which the Company in-licensed the Greater China rights from Eli Lilly. Eli Lilly had completed a Phase II trial with blosozumab in postmenopausal women in the United States and Japan. The data had shown that blosozumab can induce significant dose-dependent increases in spine, femoral neck, and total hip bone mineral density (BMD) as compared with placebo. In these studies, in the highest dose group, blosozumab treatment increased mean BMD by 17.7% at the spine and 6.2% at the total hip from baseline after 12 months. The Company obtained encouraging data from 32 Chinese patients treated with a single dose of blosozumab (TST002) and followed for 85 days, including safety, bone formation and resorption markers and BMD data. After a single dose of blosozumab (TST002) up to 1,200 mg, the average increase of lumbar spine BMD at day 85 (D85) ranged from 3.52% to 6.20% and total hip BMD from 1.30% to 2.24% across dose cohorts. The safety, efficacy and PK/PD results of this study are consistent with the clinical data in U.S. patients. The Company has received Phase II CTP from CDE and is in the process of initiating the phase IIb study.

2. TST004 (A Humanized MASP-2 mAb Candidate for IgAN)

TST004, one of the Company's key products, is a humanized mAb targeting mannan-binding lectin serine protease 2 (MASP-2) designed to prevent inflammation and tissue damage mediated by lectin pathway complement activation. It can be potentially applied to multiple MASP-2-dependent complement mediated diseases, including IgAN, a highly prevalent chronic kidney disease globally. As at the date of this announcement, it is at the Phase I stage.

3. TST801 (A Bifunctional Antibody Fusion Protein for Autoimmune Diseases)

TST801 is a first-in-class bifunctional antibody fusion protein of anti-BAFF antibody and TACI receptor. BAFF and APRIL, two ligands for TACI receptor, are involved in regulating B cell activation and differentiation. Dual targeting of BAFF and APRIL is a validated approach for the treatment of several autoimmune diseases including SLE, LN, IgAN, gMG, pSS, etc. TST801 has the potential of delivering better efficacy for the treatment of these diseases and other B-cell related autoimmune diseases. The Company has selected the lead molecule and initiated IND-enabling studies. The Company has completed the evaluation of TST801 versus other competing molecules in a mouse model of human Lupus nephritis (human BAFF overexpressing transgenic mice). TST801 demonstrated best-in-class profile in reducing memory B cells, and dsDNA, IgA, IgM and IgG as well as reducing proteinuria and kidney damage scores. As at the date of this announcement, it is at preclinical stage.

Recent Product Developments and Milestones

- The Company has completed the PK/PD study in non-human primates, and the data supports a less frequent dosing regimen compared with the benchmark molecules, and the final lead molecule was selected for the process development and IND-enabling studies.

4. TST808 (A Humanized Antibody Neutralizing APRIL, A Validated Key Target Regulating B/plasma Cell Proliferation and Survival)

TST808 is a humanized antibody neutralizing APRIL, a validated key target regulating B/plasma cell proliferation and survival. TST808 has improved properties in blocking B cell proliferation and signalling. It was engineered to achieve a longer half-life. TST808 has the potential to treat multiple autoimmune disorders including IgAN. The Company has obtained the lead molecules and initiated IND-enabling studies. The Company has engineered a second generation bi-paratopic antibody which is under preclinical evaluation. As at the date of this announcement, it is at preclinical stage.

Recent Product Developments and Milestones

- The Company has completed the PK/PD study in non-human primates, and the data supports a less frequent dosing regimen compared with the benchmark molecules, and the final lead molecule was selected for the cell line development.

5. TST008 (A Bi-specific Antibody for MASP-2 and BAFF for Autoimmune Diseases)

TST008 is a first-in-class bispecific antibody dual targeting MASP-2 and BAFF. TST008 has both effects on B cell and lectin complement pathway, which providing the potential of delivering better efficacy to diseases affected by both pathways, e.g. IgAN, SLE, LN, etc. As at the date of this announcement, it is at preclinical stage.

Cautionary Statement required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "Listing Rules"): The Company cannot guarantee that it will be able to develop, or ultimately market, any of the above drug candidates successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

III. Research and Early Development Efforts

The Company is optimising its follow-on pipeline molecules using existing technology. The Company is also employing new technologies to explore new targets to enrich its pipeline by developing the next generation of molecules. Additionally, the Company is developing antibody based targeted radioligand therapy by leveraging its antibody engineering and conjugation technologies for improving tumor/normal tissue targeting and therapeutic index. This approach could offer a new modality for multiple targets and address potential limitations of ADC due to payload resistance.

IV. Strategic Partnership to Advance Pipeline

Partnerships and collaborations are the key to maximizing the clinical and commercial potential of our assets. We have established clinical trial collaboration with BMS for osemitamab (TST001), in-licensed blosozumab (TST002) rights in the Greater China with Eli Lilly & Company and are codeveloping TST004 in China with Alebund Pharmaceuticals. Additionally, we have established multiple research collaborations, including several with companies for different ADC platforms. We also established multiple translational research collaborations with prominent academic institutions including Dana-Farber Cancer Institute and Johns Hopkins University.

Details of our existing partnerships are shown below.

1. Osemitamab (TST001)

The Company aims to develop osemitamab (TST001) as the global cornerstone treatment in Claudin18.2 expressing solid tumors including G/GEJ cancer, PDAC, and lung cancer.

In 2022, the Company established a global clinical trial collaboration with Bristol Myers Squibb (BMS) to evaluate the combination of osemitamab (TST001) with Opdivo® (nivolumab), a globally approved anti-PD-1 therapy in the first-line G/GEJ cancer, for the treatment of patients with unresectable locally advanced or metastatic Claudin18.2 expressing G/GEJ cancer. The Company has continued the clinical trial collaboration with BMS.

The Company has been discussing with multiple MNCs and other strategic collaborators on the potential global collaboration of osemitamab (TST001) for Claudin18.2 positive gastric cancer and other solid tumors. With validation of Claudin18.2 target by competing molecule in G/GEJ cancer, the Company believes osemitamab (TST001) will offer a more efficacious treatment for a broader patient population with Claudin18.2 positive G/GEJ cancer through the triple combination, that is, the combination of osemitamab (TST001), the targeted therapy, with the checkpoint inhibitor, and the first-line standard chemotherapy. The global Phase III trial (TranStar301) is designed to generate clinical evidence to support global regulatory approvals.

The Company has advanced its collaboration with Agilent for its Claudin18.2 specific CDx Assay, which is ready to be used for patient selection in our global Phase III study (TranStar301).

The Company is actively engaged in discussion globally and regional pharmaceutical companies and investment institutions to support development and commercialization and has received multiple term sheets and contract level proposals, with negotiations ongoing.

2. Blosozumab (TST002)

In 2019, the Company entered an exclusive and royalty bearing license agreement with Eli Lilly for LY-2541546 (blosozumab), LY-3108653 and LY-2950913 (each a "**Licensed Compound**"). The Company gained exclusive rights to develop, use or commercialize and manufacture the Licensed Compound in the Greater China regions including the PRC, Hong Kong, Macau and Taiwan.

The Company completed technology transfer, established manufacturing process for blosozumab (TST002), and GMP production for clinical use and all the additional preclinical studies required for IND application in China. The Company received IND Clearance from CDE and in the process of initiating the phase IIb study to validate efficacy and tolerability, and to generate necessary clinical data to support a Phase III study.

The Company has been actively discussing with multiple domestic pharmaceutical companies for the potential collaboration on the development and commercialization of blosozumab (TST002) in the Greater China. The Company is encouraged by the FDA's approval of total hip bone mineral density (BMD) as a surrogate endpoint in osteoporosis and is evaluating how to leverage this regulatory development to accelerate the clinical development of blosozumab in China.

3. TST004

The Company collaborates with Shanghai Alebund Pharmaceuticals Limited ("**Alebund Pharmaceuticals**") after establishing an equity joint venture registered under the laws of PRC in 2020 to carry out pre-clinical research and conduct clinical trials in the Greater China region. Currently, the Company has completed GMP material productions, *in vitro/in vivo* product characterization studies, non-GLP tox studies, GLP tox studies and pharmacology studies.

IND clearance has been obtained from FDA. The Company is in discussions for potential global collaboration with multiple companies including MNCs on TST004.

V. Translational Research Collaborations

The Company also entered multiple research collaborations with prominent academic institutions around the world, including the Dana-Farber Cancer Institute of Harvard Medical School, John Hopkins University, Beijing Cancer Hospital, Shanghai Pulmonary Hospital, Zhongshan Hospital, Zhongshan University, and Shanghai Jiao Tong University. The research collaborations covered osemitamab (TST001), TST003 and TST005.

The Company also established strategic collaborations with multiple technology platform companies to explore different modalities for innovative targets, including multiple ADC platforms. These research collaborations further enhanced our global leading position in Claudin18.2 targeted combination therapies and strengthened our oncology programs.

VI. Technology Partnership & Advancement

- On December 29, 2025, the Company together with its wholly-owned subsidiary, HJB (Hangzhou) Co., Ltd* (杭州奕安濟世生物藥業有限公司) ("**HJB Hangzhou**") (collectively, the "**Licensor**"), entered into strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (TWSE: 6589), a global biopharmaceutical development and manufacturing company. Under the agreement, the Company will be eligible to receive substantial upfront and milestone payments, as well as future royalty payments associated with the commercial use of Transcenta's Highly Intensified Continuous Bioprocessing (HiCB) platform. During the Reporting Period, the Company received RMB10 million upfront payment in February 2026 and RMB7 million milestone payment in May 2026 before withholding tax of technology out-licensing of HiCB.

- The Company's in-house cell culture media ExcelPro CHO are being evaluated for performance against market standards for fedbatch and perfusion processes by multiple external partners including several global leading companies of CHO cell culture media business. This provides opportunities for potential collaboration of global commercialization of ExcelPro CHO media.

VII. CDMO Business

- The total value of CDMO contracts secured by the Company increased during the first half of 2026.

- The Company established proprietary perfusion media for perfusion process, it also established basal and feed media for fed-batch process. Those media are ready for commercialization.

- The Company has completed comprehensive CMC packages to support domestic and global clients' IND filings.

- The Company has expanded its services in siRNA drug product development.

- The Company has signed a contract with a US client for a bispecific antibody IND project.

- The Company is supporting siRNA programs spanning in formulation development, drug product fill-finish, and analytical methods development.

- The Company has expanded its process development services for clients who need drug products in lyophilization dosage form.

- The Company has continued its market expansion and engaged new customers for these advanced services.

EVENTS AFTER THE REPORTING PERIOD

- As disclosed in the announcement of the Company dated July 7, 2026, the Group (through HJB (Hangzhou) Co., Ltd., a wholly owned subsidiary of the Company) entered into an amendment agreement with Eli Lilly and Company on July 7, 2026, to revert to Eli Lilly and Company two in-licensed preclinical assets (LY-3108653 and LY-2950913) for a cash consideration of US$4.0 million. Such reversion constitutes a disclosable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under Chapter 14 of the Listing Rules. Please refer to the announcement for further details.

- As disclosed in the announcement of the Company dated July 27, 2026, with effect from July 27, 2026, (i) Ms. Helen Wei Chen has been appointed as a member of the audit committee of the Board; and (ii) Mr. Jiasong Tang has been appointed as a member of the nomination committee of the Board. Further, as disclosed in the announcement of the Company dated August 28, 2026, Prof. Genhong Cheng has been appointed as an independent non-executive director of the Company with effect from August 28, 2026. Therefore, the Company has complied with Rules 3.10(1), 3.21 and 3.27A of the Listing Rules.

- As disclosed in the announcement of the Company dated August 6, 2026, on August 6, 2026, HJB (Hangzhou) Co., Ltd. entered into an asset purchase agreement with WuXi Biologics (Hangzhou) Co., Ltd., to dispose of certain CDMO assets at a total consideration of RMB190.0 million, subject to adjustments as set out in the asset purchase agreement. Such disposal constitutes a major transaction of the Company under Rule 14.06 of the Listing Rules and is subject to the reporting, announcement, circular and Shareholders' approval requirements under Chapter 14 of the Listing Rules. For further details of the Disposal, please refer to the announcement.

- The Company is in contract negotiation for an investment proposal from a major strategic investor.

- The Company is in contract negotiation for a product out-licensing partnership.

- The Company has received a new term sheet for a China rights partnership for a major product candidate.

Save as disclosed above, no material event or transaction affecting the Group and which is required to be disclosed by the Company to its shareholders has taken place after 30 June 2026.

FUTURE OUTLOOK

With respect to the development strategy, looking forward, the Company will advance its development in accordance with four core strategic initiatives to foster sustainable growth and long-term value creation, with clear objectives and actionable plans for the current year as follows:

- The Company is actively working to secure a minimum of US$100 million in funding to support the implementation of its strategic plans and sustained operational development.

- The Company will continue extensive business development and technology collaboration initiatives, leveraging strategic partnerships to broaden financing channels and attract additional funding to support its innovative pipeline development and business expansion.

- The Company will focus its internal resource on anti-osteoporosis pipelines including blosozumab (TST002), leverage external partner resources to advance oncology pipelines including osemitamab (TST001), while proactively driving business development and strategic cooperation for other pipeline assets to accelerate the advancement and value realization of all pipeline programs.

- The Company will continue to prioritize enhancing operational efficiency, implementing stringent cost control and expense management measures, optimizing resource allocation, and promoting refined operations to ensure the sustainable and healthy development of the business.

With respect to key products, the Company expects to advance in select key pipeline molecule programs and continue to strive to establish collaboration on its leading assets as well as other pipeline molecules. The Company also plans to further advance its technology platform and enhance its out-licensing for new source of revenue. A detailed breakdown of expected developments for the year 2026 is as follows:

I. Clinical Developments

Anti-Osteoporosis Pipelines

- The Company plans to initiate Phase IIb study of blosozumab (TST002) in 2026 to enable dose selection for pivotal trial.

- The Company plans to develop additional pipeline programs such as TST973 and TST901 for the treatment of osteoporosis.

Anti-Cancer Pipelines

- The Company plans to continue its efforts by leveraging external partner resources to advance its global pivotal trial (TranStar301) of osemitamab (TST001) for first-line G/GEJ cancer patients with Claudin18.2 overexpression.

- The Company will continue exploring several Claudin18.2 expressing advanced solid tumors other than G/GEJ cancer, as well as early-stage G/GEJ cancer.

- The Company plans to submit the manuscript of phase 2 study TST001-1002 results to the target journal.

- The Company will continue to explore next-generation molecules including bispecific ADC TST106 and engineered antibody based radiopharmaceutical TST198.

The Company continued to focus on forming partnerships and leveraging external resources for further development of earlier stage assets including TST013, TST003, TST786, TST801 and TST808.

II. Potential Partnerships

- The Company will continue its partnership efforts on TST001 and expects that the potential collaboration with its potential partners will move its lead asset osemitamab (TST001) into a global Phase III trial in the first line CLDN18.2 positive G/GEJ cancer, the critical first step in establishing osemitamab (TST001) as the cornerstone treatment in Claudin18.2 expressing solid tumors including G/GEJ cancer, PDAC and lung cancer.

- The Company will continue partnership discussions for our clinical assets blosozumab (TST002), TST003, TST004, and pre-clinical assets including oncology assets TST013, TST106, TST198, and TST786, as well as non-oncology assets TST808, TST801 and TST008 to maximize the value of the assets.

- The Company will continue to secure additional technology licensing deals for its HiCB technology platform and its RDC platform SEAR.

III. CMC and Technology Developments

- The Company aims to strengthen its marketing initiatives for the HiCB continuous technology platform, cell culture media products, and development services to attract industry partners for technology licensing and media business collaborations.

- The Company plans to fully develop in-house cell line expression system and be ready for internal programs and out-licensing to industry partners.

- The Company plans to increase its competitiveness by improving operational efficiency, reducing cost, improving quality, expanding new capabilities.

In light of the above, the Company is accelerating the advancement of its pipeline while actively pursuing high-impact strategic collaborations to further strengthen its global development capabilities. By continuously enhancing its products and technology platforms, the Company is driving greater operational efficiency and meaningful cost optimization. Anchored by a strong global vision and strategy, the Company is well positioned to unlock the full potential of its portfolio and deliver sustained, long-term value growth.

FINANCIAL REVIEW

Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
REVENUE	**23,597**	2,711
Cost of sales	**(6,191)**	(1,920)
Gross profit	**17,406**	791
Other income	**205**	9,426
Other gains and losses, net	**32**	(1,192)
Research and development expenses	**(51,499)**	(76,731)
Administrative and selling expenses	**(28,104)**	(28,291)
Reversal of impairment losses/(impairment losses) under expected credit loss model	**158**	(9,946)
Share of results of a joint venture	**6**	4
Finance costs	**(2,280)**	(3,968)
LOSS BEFORE TAX	**(64,076)**	(109,907)
Income tax (expense)/credit	**(3,271)**	122
LOSS FOR THE PERIOD	**(67,347)**	(109,785)
Other comprehensive income for the period		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of a foreign operation	**20**	1,001
Total comprehensive loss for the period	**(67,327)**	(108,784)
Non-IFRS measure *(Note 1)*:		
Add: Adjusted for share-based compensation expenses	**2,325**	9,339
Adjusted loss and total comprehensive loss for the period	**(65,002)**	(99,445)

[1]: See section below headed "Non-IFRS Measure" for the details of the non-IFRS measure adjustments.

SELECTED DATA FROM STATEMENT OF FINANCIAL POSITION

	At June 30, 2026 ***RMB'000*** **(Unaudited)**	At December 31, 2025 *RMB'000* (Audited)
Non-current assets	**847,127**	870,165
Current assets	**44,471**	54,668
Total assets	**891,598**	924,833
Current liabilities	**246,892**	214,414
Non-current liabilities	**91,614**	92,326
Total liabilities	**338,506**	306,740
Net current liabilities	**(202,421)**	(159,746)

1. Revenue

Contract development and manufacturing ("CDMO") services and other contract services

The Group provides CDMO services and research and development services. CDMO services stands as an integrated platform to support the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients and formulation development and dosage drug product manufacturing, for preclinical, clinical trials, new drug application, and commercial supply of chemical drugs as well as wide spectrum development from early to late stage. The research and development services are mainly for investigational new drug enabling studies based on customers' needs.

The Group primarily earns revenues by providing CDMO services and research and development services to its customers through fee-for-service ("**FFS**") contracts. Contract duration is generally a few months to two years. Under FFS method, the contracts usually have multiple deliverable units, which are generally in the form of technical laboratory reports and or samples, each with individual selling price specified within the contract. The Group identifies each deliverable unit as a separate performance obligation, and recognizes FFS revenue of contractual elements at the point in time upon finalization, delivery and acceptance of the deliverable units.

The Group's service contracts normally include payment schedules which require stage payments over the service period once certain specified milestones are reached. The Group requires certain customers to provide upfront deposits ranging from 10% to 50% of total contract sum as part of its credit risk management policies; this will give rise to contract liabilities at the start of a contract until the deliverable units have been delivered and accepted by customer. The typical credit term is 30 to 90 days upon meeting specified delivery milestones.

Out-licensing revenue

The Group entered into a strategic collaboration and non-exclusive licensing agreement with its customer to advance and expand the usage of its integrated continuous biomanufacturing technologies. The out-licensing agreements usually contain more than one unit of account, or performance obligation, including grants of the commercial use of the licensed technologies, agreements to provide research and development services and other deliverables. The out-licensing arrangements typically do not include a right of return for any deliverable. In general, the consideration allocated to each performance obligation is recognised when the respective obligation is satisfied either by delivering a good or rendering a service, limited to the consideration that is not constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as contract liabilities.

The performance obligation is satisfied at a point in time upon the transfer of certain technologies, know-hows and materials as the customer obtains the rights to use of the underlying licences and the Group usually receives non-refundable upfront payments in accordance with the license-out agreement.

Disaggregated revenue information:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
CDMO services	**5,762**	2,167
Research and development services	**835**	544
Out-licensing revenue	**17,000**	–
Timing of revenue recognition		
A point in time	**23,597**	2,711

2. Other Income

Other income consists of bank interest income and government grants. Government grants represent various subsidies granted by the PRC local government authorities to group entities as incentives for the Group's research and development activities. The government grants were unconditional and had been approved by the PRC local authorities, which are recognised when payments were received.

For the six months ended June 30, 2026, other income of our Group decreased by RMB9.2 million from RMB9.4 million for the six months ended June 30, 2025. The decrease was primarily due to the decrease of government grants we recognized during the six months ended June 30, 2026.

3. Other Gains and Losses, Net

Other net gains and losses decreased by RMB1.2 million for the six months ended June 30, 2026 from a loss of RMB1.2 million for the six months ended June 30, 2025, which is attributable to exchange rate fluctuations.

4. Research and Development Expenses

Research and development expenses primarily consist of preclinical expenses including testing fees and preclinical trial expenses, staff costs for our research and development personnel, clinical expenses including testing fees and clinical trial expenses, materials consumed for research and development of our drug candidates, depreciation and amortization expenses and others. The research and development expenses decreased by RMB25.2 million from RMB76.7 million for the six months ended June 30, 2025 to RMB51.5 million for the six months ended June 30, 2026, primarily due to the decrease in investment of our key pipeline advancement and resource reprioritization.

The following table sets forth the components of the Group's research and development expenses for the period indicated.

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Clinical expenses	**3,324**	15,005
Preclinical expenses	**402**	1,481
Staff cost	**26,275**	35,111
Materials consumed	**917**	1,217
Depreciation and amortization expenses	**17,331**	20,855
Others	**3,250**	3,062
Total	**51,499**	76,731

5. Administrative and selling expenses

Our administrative expenses decreased by RMB0.2 million from RMB28.3 million for the six months ended June 30, 2025 to RMB28.1 million for the six months ended June 30, 2026, primarily due to cost control.

Our selling expenses primarily consist of personnel cost, travel, depreciation and amortization and others. Our administrative expenses consist primarily of salaries and related benefits costs for our administrative personnel, professional fees for services provided by professional institutions, depreciation and amortization expenses, office expenses for our daily operation, traveling and transportation expenses, and others.

The following table sets forth the components of the Group's selling and administrative expenses for the period indicated.

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Salaries and related benefits costs	**16,818**	12,727
Professional fees	**4,026**	7,064
Depreciation and amortization expenses	**2,493**	2,634
Office expenses	**3,826**	3,491
Others	**941**	2,375
Total	**28,104**	28,291

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED JUNE 30, 2026

	Notes	Six months ended 30 June	
		2026	2025
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
REVENUE	*4*	**23,597**	2,711
Cost of sales		**(6,191)**	(1,920)
Gross profit		**17,406**	791
Other income		**205**	9,426
Other gains and losses, net	*5*	**32**	(1,192)
Research and development expenses		**(51,499)**	(76,731)
Administrative and selling expenses		**(28,104)**	(28,291)
Reversal of impairment losses/(impairment losses) under expected credit loss model		**158**	(9,946)
Finance costs		**(2,280)**	(3,968)
Share of results of a joint venture		**6**	4
LOSS BEFORE TAX		**(64,076)**	(109,907)
Income tax (expense)/credit	*6*	**(3,271)**	122
LOSS FOR THE PERIOD		**(67,347)**	(109,785)
Loss for the period attributable to:			
Owners of the Company		**(67,347)**	(109,785)
OTHER COMPREHENSIVE INCOME			
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:			
Exchange differences on translation of a foreign operation		**20**	1,001
OTHER COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX		**20**	1,001
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD		**(67,327)**	(108,784)
Total comprehensive loss attributable to:			
Owners of the Company		**(67,327)**	(108,784)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY			
– Basic and diluted (RMB)	*7*	**(0.16)**	(0.27)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT JUNE 30, 2026

	Notes	**At June 30, 2026** ***RMB'000*** **(Unaudited)**	At December 31, 2025 *RMB'000* (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment		**253,830**	275,592
Right-of-use assets		**19,016**	20,210
Goodwill		**471,901**	471,901
Other Intangible assets		**95,633**	95,667
Investments in a joint venture		**1,321**	1,315
Deposits paid for acquisition of property, plant and equipment		**127**	128
Value-added-tax ("**VAT**") recoverable		**4,968**	4,891
Other receivables	*8*	**181**	181
Pledged bank deposits		**150**	280
Total non-current assets		**847,127**	870,165
CURRENT ASSETS			
Inventories		**13,984**	14,018
Trade and other receivables	*8*	**20,976**	21,368
Contract costs		**5,096**	3,729
VAT recoverable		**496**	1,406
Pledged/restricted bank deposits		**424**	4
Cash and cash equivalents		**3,495**	14,143
Total current assets		**44,471**	54,668
CURRENT LIABILITIES			
Trade and other payables	*9*	**133,178**	106,615
Contract liabilities		**3,653**	574
Interest-bearing bank and other borrowings		**105,282**	102,890
Lease liabilities		**4,379**	3,935
Deferred income		**400**	400
Total current liabilities		**246,892**	214,414
NET CURRENT LIABILITIES		**(202,421)**	(159,746)
TOTAL ASSETS LESS CURRENT LIABILITIES		**644,706**	710,419

	At June 30, 2026 *RMB'000* (Unaudited)	At December 31, 2025 *RMB'000* (Audited)
NON-CURRENT LIABILITIES		
Interest-bearing bank and other borrowings	**4,850**	4,900
Lease liabilities	**11,981**	12,518
Deferred income	**50,300**	50,300
Deferred tax liabilities	**24,483**	24,608
Total non-current liabilities	**91,614**	92,326
Net assets	**553,092**	618,093
EQUITY		
Share capital	**297**	295
Treasury shares	**(2,462)**	(2,461)
Reserves	**555,257**	620,259
Total equity	**553,092**	618,093

NOTES TO THE INTERIM FINANCIAL INFORMATION

1. GENERAL INFORMATION

Transcenta Holding Limited (the "**Company**") was incorporated in the British Virgin Islands as an exempted company with limited liability on 20 August 2010, and re-domiciled to the Cayman Islands on 26 March 2021 as an exempted company with limited liability under the laws of the Cayman Islands. On 29 September 2021, the Company's shares became listed on the Main Board of The Stock Exchange of Hong Kong Limited. The address of the registered office of the Company is 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands and the principal place of business in Hong Kong is located at Room 1928, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.

The Company is an investment holding company. The Company and its subsidiaries (collectively referred to as the "**Group**") are an integrated biopharma platform that brings drug candidates from the discovery stage to the commercial stage, spanning discovery, research, development, manufacturing and commercialization.

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2025 except for the adoption of the following amended IFRS Accounting Standards for the first time for the current period's financial information.

Amendments to IFRS 9 and IFRS 7	*Amendments to the Classification and Measurement of Financial Instruments*
Amendments to IFRS 9 and IFRS 7	*Contracts Referencing Nature-dependent Electricity*
Annual Improvements to IFRS Accounting Standards – Volume 11	Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7

The nature and impact of the amended IFRS Accounting Standards are described below:

(a) Amendments to IFRS 9 and IFRS 7 Amendments to the Classification and Measurement of Financial Instruments clarify that a financial asset is derecognised when the entity's rights to the contractual cash flows expire or are transferred, while a financial liability is derecognised on the settlement date. The amendments introduce an accounting policy option to derecognise a financial liability that is settled through an electronic payment system before the settlement date if specified criteria are met. The amendments clarify how to assess the contractual cash flow characteristics of financial assets with environmental, social and governance and other similar contingent features. Moreover, the amendments clarify the requirements for classifying financial assets with non-recourse features and contractually linked instruments. The amendments also include additional disclosures for investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features. Since the Group's accounting policy for the derecognition of financial assets and liabilities in prior years aligned with the amendments and the Group did not have the financial assets that were addressed by the amendments, the amendments did not have any impact on the interim condensed consolidated financial information.

(b) Amendments to IFRS 9 and IFRS 7 Contracts Referencing Nature-dependent Electricity clarify the application of the"own-use" requirements for in-scope contracts and amend the designation requirements for a hedged item in a cash flow hedging relationship for in-scope contracts. The amendments also include additional disclosures that enable users of financial statements to understand the effects these contracts have on an entity's financial performance and future cash flows. As the Group did not have any contracts that are in the scope of the amendments, the amendments did not have any impact on the interim condensed consolidated financial information.

(c) Annual Improvements to IFRS Accounting Standards – Volume 11 set out narrow scope amendments to IFRS 1, IFRS 7 (and the accompanying Guidance on implementing IFRS 7), IFRS 9, IFRS 10 and IAS 7. The amendments include clarifications, simplifications, corrections or changes to improve consistency in the corresponding IFRS Accounting Standards. The amendments did not have any impact on the interim condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

Segment information

For the purpose of resource allocation and performance assessment, the key management of the entities and business comprising the Group, being the chief operating decision maker, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment and no further analysis of this single segment is presented.

Geographical information

(a) Revenue from external customers

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Chinese Mainland	**5,236**	2,711
United States of America	**1,361**	–
Other Asian countries and regions out of Chinese mainland	**17,000**	–
Total	**23,597**	2,711

(b) Non-current assets

The Group's non-current assets are substantially located in the PRC.

Information about major customers

Revenue from customers contributing over 10% of the total revenue of the Group are as follows:

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Customer A	**17,000**	–
Customer B	**2,969**	–
Customer C	**–**	373
Customer D	**–**	1,226
Customer E	**–**	308

4. REVENUE

Disaggregated revenue information:

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Types of goods or services		
Out-licensing revenue	**17,000**	–
CDMO services	**5,762**	2,167
Research and development services	**835**	544
Total	**23,597**	2,711
Timing of revenue recognition		
A point in time	**23,597**	2,711

5. OTHER GAINS AND LOSSES, NET

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Foreign exchange differences, net	**96**	(938)
Loss on disposal of property, plant and equipment	**(58)**	–
Others	**(6)**	(254)
Total	**32**	(1,192)

6. INCOME TAX

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current income tax *(note)*	**3,396**	3
Deferred income tax	**(125)**	(125)
Total	**3,271**	(122)

Note: the current income tax mainly represented the withholding tax arising from the consideration received under the licensing arrangement during the current interim period.

7. LOSS PER SHARE

The calculation of the basic loss per share amounts is based on the loss for the period attributable to ordinary equity holders of the Company, and the weighted average number of ordinary shares of 426,375,095 (for the six months ended 30 June 2025: 406,939,951) outstanding during the period.

No adjustment has been made to the basic loss per share amounts presented for the six months ended 30 June 2026 and 2025 in respect of a dilution as the impact of the share options had an anti-dilutive effect on the basic loss per share amounts presented.

The calculation of the basic and diluted loss per share is based on the following data:

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss		
Loss attributable to ordinary equity holders of the Company for the purpose of calculating basic loss per share	**(67,347)**	(109,785)
Shares		
Weighted average number of ordinary shares for the purpose of calculating basic loss per share	**426,375,095***	406,939,951

* The weighted average number of ordinary shares for the period shown above has been arrived after deducting the effect of the treasury shares held.

8. TRADE AND OTHER RECEIVABLES

Details of trade and other receivables are as follows:

	At 30 June	At 31 December
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade receivables	**31,251**	31,851
Less: Allowance for credit losses	**(15,515)**	(15,674)
Net carrying amount	**15,736**	16,177
Other receivables	**786**	700
Prepayments	**4,635**	4,672
	5,421	5,372
Impairment allowance	**–**	–
Net carrying amount	**5,421**	5,372
Total	**21,157**	21,549
Analysed as:		
Current portion	**20,976**	21,368
Non-current portion	**181**	181

The Group normally grants a credit period of 30-90 days or a particular period agreed with customers effective from the date when the services have been completed and accepted by customers.

The following is an aged analysis of trade receivables net of allowance for credit losses presented based on the date of completion of service at the end of each Reporting Period:

	At 30 June 2026	At 31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 1 year	**1,136**	1,559
1 – 2 years	**1**	12
2 – 3 years	**4,627**	8,503
Above 3 years	**9,972**	6,103
Total	**15,736**	16,177

9. TRADE AND OTHER PAYABLES

	At 30 June 2026	At 31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade payables	**63,872**	67,068
Accrued research and development expenses	**19,225**	18,591
Payable for purchase of property, plant and equipment	**5,546**	5,989
Loans from a related party	**11,294**	2,021
Interest payables	**85**	95
Other tax payables	**1,493**	1,348
Accrued staff costs and benefits	**17,560**	4,074
Other payables	**14,103**	7,429
Total	**133,178**	106,615

The average credit period on purchases of goods and services of the Group is 30-90 days.

The following is an aged analysis of trade payables, presented based on the earlier of the date of goods and services received and the invoice dates as at the end of the Reporting Period:

	At 30 June 2026	At 31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 30 days	**6,448**	10,970
31-120 days	**553**	6,422
121-365 days	**12,918**	8,581
1 – 2 years	**22,104**	24,094
2 – 3 years	**11,198**	8,306
Above 3 years	**10,651**	8,695
Total	**63,872**	67,068

10. DIVIDENDS

No dividends were paid, declared or proposed during the interim period. The directors of the Company have determined that no dividend will be paid in respect of the interim period.

Other Comprehensive Income (Expense)

Our other comprehensive income decreased from RMB1.0 million for the six months ended June 30, 2025 to RMB20.0 thousand for the six months ended June 30, 2026.

Non-IFRS Measure

To supplement the Group's consolidated financial statements, which are presented in accordance with the IFRS, the Company also uses adjusted loss and total comprehensive expenses for the period and other adjusted figures as additional financial measures, which are not required by, or presented in accordance with, the IFRS. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for analysis of, the Group's results of operations or financial condition as reported under IFRS. The Company's presentation of such adjusted figure may not be comparable to a similarly titled measure presented by other companies. However, the Company believes that this and other non-IFRS measures are reflections of the Group's normal operating results by eliminating potential impacts of items that the management does not consider to be indicative of the Group's operating performance, and thus facilitate comparisons of operating performance from period to period and company to company to the extent applicable.

Adjusted loss and total comprehensive expenses for the period represent the loss and total comprehensive expenses for the period excluding the effect of share-based compensation expenses. The table below sets forth a reconciliation of the loss and total comprehensive expenses for the period to adjusted loss and total comprehensive loss for the period during the periods indicated:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Total comprehensive loss for the period:	**(67,327)**	(108,784)
Add:		
Share-based compensation expenses	**2,325**	9,339
Sub-total	**2,325**	9,339
Adjusted loss and total comprehensive loss for the period	**(65,002)**	(99,445)

Employees and Remuneration Policies

The following table sets forth a breakdown of our employees as at June 30, 2026 by function:

	Number of employees	% of total number of employees
Research and Development	**67**	**44.67**
General and Administrative	**39**	**24.56**
Manufacturing	**44**	**28.66**
Total	**150**	**100**

The Group believes in the importance of attraction, recruitment and retention of quality employees in achieving the Group's success. Our success depends on our ability to attract, retain and motivate qualified personnel. The number of employees employed by the Group varies from time to time depending on our needs. Employees' remuneration is determined in accordance with prevailing industry practice and employees' educational background, experience and performance. The remuneration policy and package of the Group's employees are periodically reviewed.

Our employee remuneration comprises salaries, bonuses, social security contributions and other welfare payments. In accordance with applicable Chinese laws, we have made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees. The total employee benefit expenses for the six months ended June 30, 2026 were RMB6,788,000.

The Company also has one expired share scheme with awards outstanding and one existing share scheme, namely the Pre-IPO Equity Incentive Plan and the Share Incentive Scheme, respectively. Please refer to the section headed "Appendix IV Statutory and General Information – D. Share Schemes" in the prospectus of the Company dated September 14, 2021 (the "**Prospectus**") for further details of the Pre-IPO Equity Incentive Plan and the circular published by the Company on October 16, 2022 for further details of the Share Incentive Scheme.

During the Reporting Period, the Group did not experience any significant labour disputes or any difficulty in recruiting employees.

Liquidity and Financial Resources

On September 29, 2021, 40,330,000 ordinary shares of US$0.0001 par value each were issued at HK$16.00 per share for a total gross cash consideration of HK$645,280,000 (equivalent to RMB536,034,000).

On September 17, 2025, 14,400,000 Placing Shares were issued at the placing price of HK$4.33 per share for a total gross proceeds of approximately HK$62.35 million. For details of the use of proceeds, please refer to the section headed "Use of Net Proceeds" below.

As of June 30, 2026, bank balances and cash, pledged bank deposits and time deposits were RMB4.1 million, as compared to RMB14.4 million as of December 31, 2025. The decrease was mainly due to the cash outflows of operating activities.

Gearing Ratio

The gearing ratio of the Group was calculated using interest-bearing borrowings less cash and cash equivalents divided by (deficiency of) total equity and multiplied by 100%. The gearing ratio increased from 15.11% as at December 31, 2025 to 19.18% as at June 30, 2026.

Other Financial Information

Significant Investments, Material Acquisitions and Disposals

The Group did not make any significant investments (including any investment in an investee company with a value of five percent or more of the Group's total assets as at June 30, 2026) during the Reporting Period. The Group did not have any material acquisitions or disposals of subsidiaries, associated companies or joint ventures for the six months ended June 30, 2026.

Foreign Exchange Risk

The functional currency of the Company is Renminbi. During the Reporting Period, certain bank balances and cash, trade and other receivables, trade and other payables are denominated in U.S. dollars, which are exposed to foreign currency risk. The Group currently does not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Bank Loans and Other Borrowings

As at June 30, 2026, we have no borrowings secured by time deposits.

As at December 31, 2025, we have no borrowings secured by time deposits.

We had an aggregate of RMB110,132,250 overdrafts with fixed interest rates as at June 30, 2026.

Contingent Liabilities

As at June 30, 2026, the Group did not have any material contingent liabilities.

Funding and Treasury Policy

The Group adopts a prudent funding and treasury policy; the management team and the Board monitor and evaluate the financial conditions and liquidity from time to time and on a regular basis, to ensure the Group's assets, liabilities and commitments can meet the funding requirements.

Going Concern Issues and Updates on Mitigation Plans and Measures

Going concern issues

The Group incurred a net loss of RMB67,347,000 and a net operating cash outflow of RMB18,913,000 for the six months ended June 30, 2026 and the Group has net current liabilities of approximately RMB202,421,000 and capital commitments of approximately RMB193,000 as at June 30, 2026. These conditions may cast significant doubt on the Group's ability to continue as a going concern.

Since the publication of the Company's annual report for the year ended December 31, 2024 (the "**2024 Annual Report**"), the Group has been undertaking a number of measures and actions, as well as following up on existing ones to mitigate its liquidity pressure and improve its financial position, for which updates on the implementation progress, status and expected outcome were disclosed in the announcements of the Company dated July 11, 2025, October 22, 2025 and January 22, 2026 (the "**Progress Updates**").

The Management's assessment

The management of the Group has given careful consideration to the above conditions and their potential impact on the Group's ability to continue as a going concern during the preparation of the condensed consolidated financial statements for the Reporting Period ("**Condensed Consolidated Financial Statements**"). The management of the Group has prepared the Group's cash flow projection, which covers a period of not less than twelve months from June 30, 2026 (the "**Cashflow Projection**") and has given due consideration to the matters that give rise to material doubt as to its ability to continue as a going concern, and accordingly, has been proactively following through on the plans as disclosed in the 2024 Annual Report and the Progress Updates.

The Directors' view

The Directors, having perused the information prepared by the management, including but not limited to the Cashflow Projection, the Progress Updates, and taking into account the management's report on the latest progress thereto and plans going forward, have (on the basis that such latest plans and measures (as set forth below) are and will be effectively implemented as planned) come to the view that the Group will have sufficient financial resources to finance its operations and meet its financial obligations when they fall due within twelve months from the date of approval of the Condensed Consolidated Financial Statements. Accordingly, the Directors have, at the time of approving the Condensed Consolidated Financial Statements, a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Save for the matters disclosed herein, the Directors are not aware of any other events or conditions that may cast significant doubt upon the Company's ability to continue as a going concern, and thus it is appropriate for the Condensed Consolidated Financial Statements to be prepared on a going concern basis.

Updates on the latest plans and measures taken or to be taken

A summary of the latest plans and measures taken or to be taken to support such going concern assumptions, which have been considered, recommended and agreed by the audit committee of the Company (the "**Audit Committee**") after its critical review of the management's position for the six months ended June 30, 2026 is set forth as follows:

i. Engaging with various third parties to further its global development and commercialization of a major pipeline, with "licensing out" and/or "co-development plans"

The Group continued to advance discussions for the development and commercialization of its lead asset osemitamab (TST001) with multiple global and regional pharmaceutical companies and investment institutions. During the period, the Company continued due-diligence, technical and commercial discussions with interested parties regarding potential global and/or regional collaboration and financing structures. Certain discussions have progressed to term-sheet and/or contract negotiation, pending the fulfillment of certain conditions. The Company continues to pursue a transaction or financing structure to leverage partnerships and external resources in support of initiating the global Phase 3 trial for first-line Claudin18.2-positive gastric/gastroesophageal junction cancer.

ii. Pursuing out-licensing or fund raising to support further development of other pipelines

The Group continued active partnering and financing discussions regarding its other pipeline programs, including blosozumab (TST002), TST003, TST013, TST198, TST801, TST808, and ozekibart. Multiple parties have conducted scientific, technical, intellectual property, and commercial due diligence reviews for potential global or regional licensing, joint development, or other collaboration arrangements. Certain discussions have progressed to term-sheet and/or contract negotiation stage.

The Group also continued to evaluate asset-level financing and NewCo structures to attract dedicated external capital for selected portfolios. The Company has prioritized structures that preserve the value and future partnering flexibility of its retained program intellectual property, technology intellectual property and know-how.

In addition, the Group entered into an amendment agreement with Eli Lilly and Company on July 7, 2026, pursuant to which the Group agreed to revert two preclinical licensed assets to Lilly for cash consideration of US$4.0 million. The licensing arrangements relating to blosozumab (TST002) remain unaffected and in full force and effect.

The Company is also exploring approaches to leverage external partnerships, third-party funding, and internal expertise to advance the development of novel and differentiated pipeline assets.

iii. Engaging in discussions and negotiations with various parties for capital funding

The Group continued to pursue diversified financing channels and instruments. Since the publication of the 2025 Annual Report, the Company has maintained active engagement with strategic and institutional investors and financial intermediaries. Certain discussions have continued at the term-sheet and/or contract negotiation stage, subject to market conditions, due diligence, definitive documentation and customary corporate and regulatory approvals.

The Company continues to evaluate financing proposals alongside potential business development proceeds and other strategic transactions, aimed at strengthening the Group's balance sheet and funding its prioritized R&D programs. The Company maintains an indicative fundraising target of up to US$100 million, subject to market conditions and customary approvals.

iv. Exploring non-exclusive, royalty-bearing proprietary technology platform out-licensing opportunities

Following the strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. in respect of the Group's Highly Intensified Continuous Bioprocessing (HiCB) platform, the Group received the RMB10 million upfront payment and an additional RMB7 million milestone payment in May before withholding tax and continued to support the agreed technology-transfer and implementation activities. The Group remains eligible to receive further milestone payments and royalties associated with commercial use of the licensed technologies.

The Group continued parallel discussions with biotechnology companies, contract development and manufacturing organizations and other industry participants regarding the evaluation and potential licensing of its continuous bioprocessing, expression-system and related proprietary manufacturing technologies.

v. Exploring global partnerships in perfusion and fed-batch culture media supply, as well as other co-development and licensing opportunities

The Group continued collaborations and technical evaluations with global and regional cell-culture-media suppliers and industry partners. These activities are intended to support commercialization of the Group's perfusion and fed-batch media technologies, generate recurring technology licensing and product-associated revenue streams, and deepen strategic relationships across the global biomanufacturing supply chain.

The Group has also continued discussions with potential partners concerning integrated arrangements combining cell-line expression systems, media, continuous perfusion processing and related development support. Certain discussion has progressed to term-sheet negotiation stage.

vi. Negotiating with banks to renew and extend existing bank borrowings, and secure new bank facilities

As disclosed in the 2025 Annual Report, the Group obtained a new credit facility of RMB43 million and drew down a new bank loan of RMB13 million following the end of 2025. The Group continues to maintain constructive relationships with its banking partners, pursue the renewal and extension of existing facilities, and evaluate additional banking and credit resources to support day-to-day operations and prioritized R&D expenditures. Since the last disclosure, the Group has successfully completed approximately RMB85 million in bank loan renewals and extensions.

vii. Negotiating with suppliers to extend repayment dates of the overdue payables

The Group continued constructive dialogue with major suppliers regarding payment arrangements. The Group has agreed or continued to implement revised payment schedules and extensions with certain suppliers, improving short-term cash-flow flexibility while supporting continuity of critical research, development and operating activities.

viii. Prospecting and engaging new contract development and manufacturing (CDMO) customers

The Group continued to serve existing CDMO customers and pursue selected new domestic and international opportunities across process development, analytical development, drug-product formulation, fill-and-finish and other service models. The Group's continuous bioprocessing, cell-line and media capabilities continue to support differentiated technical offerings.

ix. Implementing initiatives to align resources more effectively and efficiently with strategic objectives

The Group has maintained rigorous cost discipline across its operations and continued to implement further efficiency initiatives in line with its focused business strategy. For the six months ended 30 June 2026, compared with the corresponding period in 2025, the Group achieved a 28% reduction in labor expenses and a 24% reduction in operating expenses, both calculated on a cash basis.

These actions, together with proceeds from completed and potential business development transactions, financing activities and other strategic initiatives, are intended to preserve liquidity and extend the Group's cash runway.

In parallel, the Group has been evaluating strategic options to optimize the capital intensity and cost structure of its manufacturing and CDMO operations while retaining its drug-program and intellectual property, proprietary technology platforms and know-how, and the clinical, regulatory and CMC capabilities required to advance its core biopharmaceutical business. Any future manufacturing model is expected to preserve access to the manufacturing and technical support needed for the Group's retained programs.

Audit Committee's review

The Audit Committee has reviewed the facts and circumstances leading to such going concern issue, discussed with the management of the Company the management's assessment of the Cashflow Projection and the Progress Updates, and taken into account the Directors' view thereon and the latest plans and measures undertaken (and continue to focus on) by the Group to support the going concern assumptions used in preparation of the Condensed Consolidated Financial Statements. After careful analysis and prudent assessment of the aforementioned plans and measures (if effectively implemented) in mitigating the liquidity burden, optimising the Group's operations and improving its financial position, the Audit Committee concurs with the Directors' assessment and the basis for forming such a view with respect to adopting going concern assumptions in the preparation of the Condensed Consolidated Financial Statements.

CORPORATE GOVERNANCE AND OTHER INFORMATION

The Company was incorporated under the laws of the British Virgin Islands on August 20, 2010 and continued in the Cayman Islands on March 26, 2021 as an exempted company with limited liability, and the Shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on September 29, 2021 (the "**Listing Date**").

The Company is committed to maintaining and promoting stringent corporate governance. The principle of the Company's corporate governance is to promote effective internal control measures and to enhance the transparency and accountability of the Board to all Shareholders.

The Company has adopted the principles and code provisions set out in the Corporate Governance Code contained in Appendix C1 (as amended from time to time) to the Listing Rules (the "**CG Code**") as the basis of the Company's corporate governance practices.

The Board is committed to achieving high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for the Group to safeguard the interests of Shareholders and to enhance corporate value and accountability.

Compliance with the Corporate Governance Code

During the Reporting Period, the Company has applied the principles of and complied with all the applicable code provisions set out from time to time in the CG Code, save and except for code provision C.2.1 of Part 2 of the CG Code as explained below.

Code provision C.2.1 of Part 2 of the CG Code stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. The Company does not have a separate chairman and chief executive officer and Dr. Xueming Qian currently performs these two roles. The Board believes that vesting the roles of both chairman and chief executive officer in the same person has the benefit of ensuring consistent leadership within the Group and enables more effective and efficient overall strategic planning for the Group. The Board considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively. The Board will continue to review and consider splitting the roles of chairman of the Board and the chief executive officer of the Company at a time when it is appropriate by taking into account circumstances of the Group as a whole.

Further information on the corporate governance practice of the Company will be disclosed in the annual report of the Company for the year ended December 31, 2026. The Company will continue to regularly review and monitor its corporate governance practices to ensure compliance with the CG Code, and maintain a high standard of corporate governance practices of the Company.

Compliance with the Model Code for Securities Transactions by Directors

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 (as amended from time to time) to the Listing Rules as its own securities dealing code to regulate all dealings by Directors and relevant employees in securities of the Company and other matters covered by the Model Code.

The provisions under the Listing Rules in relation to compliance with the Model Code by the Directors regarding securities transactions have been applicable to the Company since the Listing Date. Having made specific enquiry, all the Directors have confirmed that they have complied with the Model Code during the Reporting Period.

No incident of non-compliance with the Model Code was noted by the Company during the Reporting Period.

Purchase, Sale or Redemption of the Company's Listed Securities

During the Reporting Period and up to the date of this announcement, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's securities (including any sale of treasury shares (as defined under the Listing Rules)) listed on the Stock Exchange. As at June 30, 2026, the Company held 2,516,500 treasury shares, which may be used for transfer or for share grants under share schemes that comply with Chapter 17 of the Listing Rules, resale at market price to raise additional funds when the Company thinks appropriate, and for other purposes permitted under the Listing Rules, the Articles of Association and the applicable laws of the Cayman Islands, subject to market conditions and our Group's capital management needs.

Material Litigation

The Company was not involved in any material litigation or arbitration during the Reporting Period. The Directors are also not aware of any material litigation or claims that were pending or threatened against the Group during the Reporting Period.

Future Plans for Material Investment or Capital Assets

Save as disclosed in this announcement, the Group does not have other plans for material investments and capital assets as at the date of this announcement.

USE OF NET PROCEEDS

References are made to the announcement of the Company dated September 10, 2025 in respect of the placing of new Shares under the General Mandate, the announcement of the Company dated September 17, 2025 in respect of completion of placing of new shares under General Mandate, and the "Use of Net Proceeds" as disclosed in the annual results announcement for the year ended 2025.

The unutilized net proceeds from the placing as at June 30, 2026 amounted to approximately HK$3.37 million and are expected to be fully utilized on or before December 31, 2026, in accordance with the intended use as disclosed in the announcement of the Company dated 10 September 2025. The Board confirms that there has been no material change in the intended use of proceeds from the placing as previously disclosed. The Company intends to apply the net proceeds from the placing as follows:

Use of Net Proceeds from the Placing	% of Net Proceeds	Net Proceeds from the Placing	Amount of utilized Net Proceeds as at June 30, 2026	Amount of unutilized Net Proceeds as at June 30, 2026	Expected timeline of full utilization
Clinical development of pipeline assets, including TST001 and TST002	40%	HK$23.74 million	HK$23.74 million	HK$0 million	On or before December 31, 2026
Advancement of pre-clinical-stage pipeline assets with near-term out-licensing potential, including TST801, TST013 and TST786	30%	HK$17.80 million	HK$14.43 million	HK$3.37 million	On or before December 31, 2026
Working capital and general corporate purposes, including general business operations and business development	30%	HK$17.80 million	HK$17.80 million	HK$0 million	On or before December 31, 2026
Total	**100%**	**HK$59.34 million**	**HK$55.97 million**	**HK$3.37 million**	

Also, as regards the net proceeds from the Global Offering, as disclosed in the "Use of Net Proceeds" in the annual results announcement for the year ended 2025 on the utilization of the remaining unutilized Net Proceeds, such net proceeds had been fully utilized as at December 31, 2025.

Audit Committee

The Company has established the Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the CG Code. The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal controls system of our Group, review and approve connected transactions (if any) and provide advice and comments to the Board. The Audit Committee comprises three members, namely Mr. Jiasong Tang (唐稼松), Ms. Helen Wei Chen (陳瑋) and Dr. Li Xu (徐莉), with Mr. Jiasong Tang (唐稼松) (being our independent non-executive Director with the appropriate professional qualifications) as chairperson of the Audit Committee.

The Audit Committee has reviewed the unaudited consolidated financial statements of the Group for the six months ended June 30, 2026. The Audit Committee has also discussed matters with respect to the accounting policies and practices adopted by the Company, internal control and financial reporting matters with senior management members of the Group. The Audit Committee considers that this announcement is in compliance with the relevant accounting standards, rules and regulations and appropriate disclosures have been duly made.

Other Board Committees

In addition to the Audit Committee, the Company has also established a nomination committee and a remuneration committee.

INTERIM DIVIDEND

The Board does not recommend the distribution of an interim dividend for the six months ended June 30, 2026.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement has been published on the websites of the Stock Exchange (**http://www.hkexnews.hk**) and the Company (**http://www.transcenta.com/**).

The 2026 interim report of the Group for the six months ended June 30, 2026 will be published on the aforesaid websites of the Stock Exchange and the Company and will be dispatched to the Company's shareholders who have already provided instructions indicating their preference to receive hard copies in due course.

APPRECIATION

The Board would like to express its sincere gratitude to the Shareholders, management team, employees, business partners and customers of the Group for their support and contribution to the Group.

By order of the Board
Transcenta Holding Limited
Xueming Qian
Executive Director, Chairman and Chief Executive Officer

Hong Kong, August 28, 2026

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Xueming Qian as executive Director, chairman and chief executive officer; (ii) Dr. Li Xu and Dr. Han Sen Xu as non-executive Directors; and (iii) Mr. Jiasong Tang, Ms. Helen Wei Chen and Prof. Genhong Cheng as independent non-executive Directors.